PDCD1 and head and neck squamous cell carcinoma: Immune checkpoint inhibitors (ICIs), including anti-PD-1 antibodies Pembrolizumab and Nivolumab, have shown promising results in patients with R/M HNSCC However, only 15 to 20% of patients benefit from single-agent ICI (19).